statistiche ricercatore

BARTALENA, LUIGI

Distribuzione geografica

Continente	#
NA - Nord America	20.986
EU - Europa	12.750
AS - Asia	3.051
Continente sconosciuto - Info sul continente non disponibili	43
SA - Sud America	39
OC - Oceania	19
AF - Africa	14
Totale	36.902

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	20.955
IT - Italia	6.211
UA - Ucraina	2.451
TR - Turchia	1.392
SE - Svezia	953
DE - Germania	890
VN - Vietnam	799
IE - Irlanda	698
CN - Cina	663
FI - Finlandia	593
GB - Regno Unito	481
FR - Francia	115
RU - Federazione Russa	113
JP - Giappone	62
IN - India	61
EU - Europa	41
CZ - Repubblica Ceca	36
NL - Olanda	36
BE - Belgio	32
CA - Canada	25
ES - Italia	22
BR - Brasile	18
CH - Svizzera	17
AT - Austria	16
CL - Cile	15
NZ - Nuova Zelanda	13
RO - Romania	13
HK - Hong Kong	12
PK - Pakistan	11
BY - Bielorussia	8
SG - Singapore	8
AU - Australia	6
BG - Bulgaria	6
EG - Egitto	6
HU - Ungheria	6
MY - Malesia	6
HR - Croazia	5
IL - Israele	5
LU - Lussemburgo	5
NO - Norvegia	5
AE - Emirati Arabi Uniti	4
EE - Estonia	4
GR - Grecia	4
MD - Moldavia	4
PL - Polonia	4
RS - Serbia	4
SK - Slovacchia (Repubblica Slovacca)	4
AR - Argentina	3
BA - Bosnia-Erzegovina	3
BD - Bangladesh	3
DK - Danimarca	3
LK - Sri Lanka	3
PA - Panama	3
SI - Slovenia	3
TZ - Tanzania	3
A2 - ???statistics.table.value.countryCode.A2???	2
AZ - Azerbaigian	2
BN - Brunei Darussalam	2
IQ - Iraq	2
IR - Iran	2
KR - Corea	2
LT - Lituania	2
MM - Myanmar	2
MX - Messico	2
PH - Filippine	2
PT - Portogallo	2
TH - Thailandia	2
AM - Armenia	1
BO - Bolivia	1
BT - Bhutan	1
CV - Capo Verde	1
GE - Georgia	1
GL - Groenlandia	1
IM - Isola di Man	1
KE - Kenya	1
KW - Kuwait	1
MA - Marocco	1
NG - Nigeria	1
PE - Perù	1
PY - Paraguay	1
TW - Taiwan	1
UZ - Uzbekistan	1
ZA - Sudafrica	1
Totale	36.902

Salva come PNG Salva come JPEG

Città	#
Milan	4.529
Fairfield	3.227
Jacksonville	1.896
Woodbridge	1.881
Chandler	1.671
Ashburn	1.555
Houston	1.356
Seattle	1.332
Wilmington	1.246
Cambridge	1.080
Dearborn	1.073
Ann Arbor	971
Izmir	725
Dublin	688
Princeton	678
Nyköping	420
Dong Ket	410
Rome	328
Como	239
San Mateo	238
San Diego	201
New York	132
Ogden	123
Beijing	109
Düsseldorf	86
Hefei	82
Kunming	74
Washington	68
London	65
Zhengzhou	65
Kocaeli	60
Norwalk	60
Dallas	58
Tokyo	57
Nanjing	56
Redmond	51
Boardman	45
Los Angeles	40
Jinan	33
Helsinki	32
Brussels	31
Verona	31
Brno	30
Guangzhou	28
Nanchang	25
Frankfurt am Main	22
Pune	19
Kilburn	18
Munich	18
Shanghai	17
Berlin	15
Edinburgh	15
Hebei	14
Redwood City	13
Toronto	13
Madrid	12
Shenyang	12
Vienna	12
Acton	11
Chicago	11
Fuzhou	11
São Paulo	11
Amsterdam	10
Chengdu	10
New Bedfont	10
Stockholm	10
Chiswick	9
Detroit	9
Phoenix	9
San Francisco	9
Tappahannock	9
Piacenza	8
Shaoxing	8
Auburn Hills	7
Auckland	7
Changsha	7
Falls Church	7
Hounslow	7
Islamabad	7
Quzhou	7
Budapest	6
Hanoi	6
Kuala Lumpur	6
Leinì	6
Singapore	6
Sofia	6
Southwark	6
Wandsworth	6
Zurich	6
Atlanta	5
Baotou	5
Chongqing	5
Hyderabad	5
Mountain View	5
Paris	5
Pavia	5
Philadelphia	5
Prescot	5
Varese	5
Wuhan	5
Totale	27.688

Salva come PNG Salva come JPEG

Nome	#
Vitreous Substitutes: The Present and the Future.	250
Macular hole surgery: The healing process of outer retinal layers to visual acuity recovery	230
A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases.	197
Simultaneous medullary and papillary thyroid cancer: two case reports.	196
A 2013 European survey of clinical practice patterns in the management of Graves' disease	185
Pituitary apoplexy during pregnancy: A rare, but dangerous headache	182
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study	182
PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012	181
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	179
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?	178
Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management	175
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy	173
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?	173
Masked hypertension in newly diagnosed hypothyroidism: a pilot study	172
Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study	167
Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs	165
The clinical enigma of the “Flea catcher” by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?	165
Serum TSH measurements by a sensitive enzyme immunoassay discriminate euthyroid from hyperthyroid subjects and avoid the need for TRH test during suppressive therapy with L-thyroxine	163
Physical performance in newly diagnosed hypothyroidism: a pilot study	162
Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone	160
The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.	160
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO	158
Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy	157
Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe	155
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review	155
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?	154
Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy	153
Studies on the occurrence of ophthalmopathy in Graves' disease	153
Lack of nocturnal serum thyrotropin surge after surgery	152
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)	152
Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism	152
Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases	150
Characterization of nascent and secreted thyroxine-binding globulin in cultured human hepatoma (Hep G2) cells	150
Interference of thyroglobulin in TSAb detection by radioreceptor assay	150
Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology consensus statement	149
Radioactive iodine thyroid uptake in patients with amiodarone iodine-induced thyroid dysfunction	148
Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids	148
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study	148
More on smoking habits and Graves' ophthalmopathy	147
Can a patient-tailored treatment approach for Graves' disease reduce mortality?	147
Graves' orbitopathy: imperfect treatments for a rare disease	146
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.	145
The effect of altered thyroid function on serum fructosamine concentrations	145
Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism	144
Shortening Hospital Stay for Thyroid Surgery.	144
The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study	142
Free thyroxine values in dried blood spots on filter paper in newborns are related to both gestational age and birth body weight	142
Plasma total and acylated ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction	142
Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients	141
Comparison between thyroid-stimulating and TSH-binding inhibiting immunoglobulins of Graves' disease	141
Pain perception, blood pressure levels, and peripheral benzodiazepine receptors in patients followed for differentiated thyroid carcinoma: a longitudinal study in hypothyroidism and during hormone treatment	141
Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association	141
Graves' orbitopathy: do not give it for granted	141
Cigarette smoking: Number one enemy for Graves ophthalmopathy	140
Effects of the antileukemic drug L-asparaginase on sex-hormone binding globulin: studies in vivo and in vitro	139
Human serum thyrotrophin measurement by ultrasensitive immunoradiometric assay as a first-line test in the evaluation of thyroid function	139
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association	139
Treatment of hyperthyroidism in patients with Graves' orbitopathy	139
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial	139
Graves'-like orbitopathy: do not forget IgG4-related disease	139
Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature	138
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?	138
Diagnosis of amiodarone iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness	137
Changes in radioimmunoassayable prealbumin (TBPA) serum levels from birth to adulthood	137
Radioiodine therapy and Graves' ophthalmopathy	137
Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy	136
The age of patients with thyrotoxicosis factitia in Italy from 1973 to 1996	136
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal	136
Medullary thyroid carcinoma: surgical treatment advances	136
Effect of amiodarone on circulating antithyroid antibodies	135
High prevalence of subacute thyroiditis during summer season in Italy	134
Polymorphism of human thyroxine-binding globulin	133
Biosynthesis of a novel thyroxine-binding protein (27 K protein) in human hepatoma (Hep G2) cells	133
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels:studies in vivo by color flow Doppler sonography	133
The challenge of orbital decompression in a patient with multiple autoimmune diseases and Graves' orbitopathy: a case report and review of the literature	133
Radioreceptor assay of TSH: its use to detect thyroid-stimulating immunoglobulins	132
Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement	132
Radioimmunoassay of thyroid hormones	131
Measurement of thyroid cell surface antibodies by radioassay using human cultured thyroid cells	131
Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study	131
Treating Graves' orbitopathy: where are we?	131
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study	131
Orbital radiotherapy for Graves' ophthalmopathy	130
Amiodarone and the thyroid	130
Thyroid hormone treatment for differentiated thyroid carcinoma: What drug, how long, what dose?	130
Graves' disease and Turner's syndrome	129
Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism	129
Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (Hep G2) cells	129
Management of Graves' ophthalmopathy: reality and perspectives	129
Long-term safety of orbital radiotherapy for Graves' ophthalmopathy	129
Graves' ophthalmopathy: state of the art and perspectives	129
Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy	129
Graves' orbitopathy: imperfect treatments for a rare disease	129
Ontogeny of nyctohemeral variations of thyrotropin-releasing hormone in rat hypothalamus	128
The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective	128
Orbital radiotherapy for Graves' ophthalmopathy: useful or useless? Safe or dangerous?	127
Epidemiology and prevention of Graves' ophthalmopathy	127
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study	127
Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey	127
Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations	127
Totale	14.766

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	129.204
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	129.204

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	7.808	0	264	382	1.518	626	1.133	1.199	977	594	502	132	481
2020/2021	5.749	116	557	194	623	297	643	398	476	823	315	498	809
2021/2022	3.604	378	466	263	137	197	145	175	185	268	573	308	509
2022/2023	4.443	499	248	394	427	322	956	4	544	594	153	179	123
2023/2024	7.528	1.102	1.179	1.142	1.447	1.540	507	55	160	194	55	23	124
2024/2025	83	26	57	0	0	0	0	0	0	0	0	0	0
Totale													37.140